Abstract
Systemic sclerosis (SSc) is characterized by vascular alterations, activation of the immune system and tissue fibrosis. Vascular insufficiency manifests early in the disease, and although there is evidence of an active repair process, capillaries deteriorate and regress. Factors that contribute to the failure of vascular regeneration might include persistent injury, an imbalance between proangiogenic and antiangiogenic mediators, intrinsic abnormal properties of the cellular components of the vessels, and the presence of fibroblast-derived antiangiogenic factors. In addition, circulating dysfunctional endothelial progenitor cells might further exacerbate vessel deterioration. Abnormal expression of transcription factors, including Fra2 and Fli1, has been proposed to contribute to SSc vasculopathy. Fli1 regulates genes that are involved in vessel maturation and stabilization, suggesting that reduced levels of Fli1 in SSc vasculature could contribute to the development of unstable vessels that are prone to regression. Conversely, proliferating endothelial cells and pericytes, in the presence of an appropriate stimulus, might transdifferentiate into collagen-producing cells, and thus contribute to the initiation of fibrosis. Despite progress in treating the symptoms of vascular disease in SSc, the underlying mechanisms remain poorly understood. An improved knowledge of the molecular and cellular pathways that contribute to SSc vasculopathy could help in the design of effective therapies in the future.
Key Points
-
Systemic sclerosis (SSc) is initiated by endothelial cell injury; this event leads to progressive structural defects in microvessels
-
There is evidence of enhanced angiogenic activity early in the disease
-
Multiple factors might contribute to defective vascular repair and regeneration
-
Intrinsic pathogenic alterations in endothelial cells might be a key factor that interferes with the vascular repair process
-
Aberrant expression of endothelial transcription factors, including Fra2, Fli1, peroxisome proliferator-activated receptor γ and GATA-6, has been associated with SSc, and might contribute to vascular defects
-
Endothelial cells and pericytes could represent a source of activated fibroblasts early in the disease
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sapadin, A. N., Esser, A. C. & Fleischmajer, R. Immunopathogenesis of scleroderma—evolving concepts. Mt Sinai J. Med. 68, 233–242 (2001).
Varga, J. & Abraham, D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557–567 (2007).
Bakst, R., Merola, J. F., Franks, A. G. Jr & Sanchez, M. Raynaud's phenomenon: pathogenesis and management. J. Am. Acad. Dermatol. 59, 633–653 (2008).
LeRoy, E. C. & Medsger, T. A. Jr. Raynaud's phenomenon: a proposal for classification. Clin. Exp. Rheumatol. 10, 485–488 (1992).
Koenig, M. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58, 3902–3912 (2008).
Kahaleh, B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum. Dis. Clin. North Am. 34, 57–71 (2008).
Herrick, A. L. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 44, 587–596 (2005).
Wigley, F. M. Vascular disease in scleroderma. Clin. Rev. Allergy Immunol. 36, 150–175 (2009).
Brown, G. E. & O'Leary, P. A. Skin capillaries in scleroderma. Arch. Intern. Med. 36, 73–88 (1925).
Campbell, P. M. & LeRoy, E. C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin. Arthritis Rheum. 4, 351–368 (1975).
Michalowski, R. & Kudejko, J. Electron microscopic observations on skeletal muscle in diffuse scleroderma. Br. J. Dermatol. 78, 24–28 (1966).
Freemont, A. J., Hoyland, J., Fielding, P., Hodson, N. & Jayson, M. I. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br. J. Dermatol. 126, 561–568 (1992).
Prescott, R. J., Freemont, A. J., Jones, C. J., Hoyland, J. & Fielding, P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J. Pathol. 166, 255–263 (1992).
Cool, C. D., Kennedy, D., Voelkel, N. F. & Tuder, R. M. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum. Pathol. 28, 434–442 (1997).
Dorfmuller, P. et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum. Pathol. 38, 893–902 (2007).
Nagai, Y. et al. Autopsy case of systemic sclerosis with severe pulmonary hypertension. J. Dermatol. 34, 769–772 (2007).
Cannon, P. J. et al. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 53, 1–46 (1974).
Adams, R. H. & Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8, 464–478 (2007).
Papetti, M. & Herman, I. M. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282, C947–C970 (2002).
Fleischmajer, R. & Perlish, J. S. [3H]Thymidine labeling of dermal endothelial cells in scleroderma. J. Invest. Dermatol. 69, 379–382 (1977).
Kazandjian, S., Bruneval, P., Fiessinger, J. N., Camilleri, J. P. & Housset, E. Active proliferation of telangiectases in skin of patients with progressive systemic sclerosis (PSS). Arch. Dermatol. Res. 279, 8–11 (1986).
Kazandjian, S., Fiessinger, J. N., Camilleri, J. P., Dadoune, J. P. & Housset, E. Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study. Acta Derm. Venereol. 62, 425–429 (1982).
Dong, C. et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc. Natl Acad. Sci. USA 99, 3908–3913 (2002).
Ribatti, D. et al. Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. Clin. Rheumatol. 17, 115–120 (1998).
Beon, M., Harley, R. A., Wessels, A., Silver, R. M. & Ludwicka-Bradley, A. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin. Exp. Rheumatol. 22, 733–742 (2004).
Distler, O. et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 4, R11 (2002).
Hummers, L. K., Hall, A., Wigley, F. M. & Simons, M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J. Rheumatol. 36, 576–582 (2009).
Davies, C. A., Jeziorska, M., Freemont, A. J. & Herrick, A. L. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum. Pathol. 37, 190–197 (2006).
Distler, O. et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ. Res. 95, 109–116 (2004).
Mackiewicz, Z. et al. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin. Exp. Rheumatol. 20, 641–646 (2002).
Dor, Y. et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21, 1939–1947 (2002).
Koch, A. E. & Distler, O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res. Ther. 9 (Suppl. 2), S3 (2007).
Mulligan-Kehoe, M. J. et al. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum. 56, 3448–3458 (2007).
Urbich, C. & Dimmeler, S. Endothelial progenitor cells functional characterization. Trends Cardiovasc. Med. 14, 318–322 (2004).
Yoder, M. C. Defining human endothelial progenitor cells. J. Thromb. Haemost. 7 (Suppl. 1), 49–52 (2009).
Purhonen, S. et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl Acad. Sci. USA 105, 6620–6625 (2008).
Kilarski, W. W., Samolov, B., Petersson, L., Kvanta, A. & Gerwins, P. Biomechanical regulation of blood vessel growth during tissue vascularization. Nat. Med. 15, 657–664 (2009).
Westerweel, P. E. & Verhaar, M. C. Endothelial progenitor cell dysfunction in rheumatic disease. Nat. Rev. Rheumatol. 5, 332–340 (2009).
Zhu, S. et al. Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells. Circulation 118, 2156–2165 (2008).
Cipriani, P. et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 56, 1994–2004 (2007).
Kuwana, M. et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum. 54, 1946–1951 (2006).
Fleming, J. N. et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3, e1452 (2008).
Asano, Y. et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am. J. Pathol. 176, 1983–1998 (2010).
Rajkumar, V. S. et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther. 7, R1113–R1123 (2005).
Giusti, B. et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res. Ther. 8, R115 (2006).
Taddei, A. et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat. Cell Biol. 10, 923–934 (2008).
Gargalovic, P. S. et al. The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 26, 2490–2496 (2006).
Lenna, S. et al. HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cells. J. Immunol. 184, 4654–4661 (2010).
Sgonc, R. et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J. Clin. Invest. 98, 785–792 (1996).
Margheri, F. et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, β2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 54, 3926–3938 (2006).
Serrati, S. et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J. Pathol. 210, 240–248 (2006).
Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685–693 (2003).
Kutcher, M. E. & Herman, I. M. The pericyte: cellular regulator of microvascular blood flow. Microvasc. Res. 77, 235–246 (2009).
Rajkumar, V. S., Sundberg, C., Abraham, D. J., Rubin, K. & Black, C. M. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 42, 930–941 (1999).
Manzur, M. & Ganss, R. Regulator of G protein signaling 5: a new player in vascular remodeling. Trends Cardiovasc. Med. 19, 26–30 (2009).
Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410–414 (2008).
Helmbold, P., Fiedler, E., Fischer, M. & Marsch, W. Hyperplasia of dermal microvascular pericytes in scleroderma. J. Cutan. Pathol. 31, 431–440 (2004).
Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3, 422–433 (2003).
Hoyland, J. A., Newson, L., Jayson, M. I. & Freemont, A. J. The vascular basement membrane in systemic sclerosis skin: heterogeneity of type IV collagen. Br. J. Dermatol. 129, 384–388 (1993).
Zenz, R. et al. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res. Ther. 10, 201 (2008).
Eferl, R. et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc. Natl Acad. Sci. USA 105, 10525–10530 (2008).
Maurer, B. et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 120, 2367–2376 (2009).
Oikawa, T. & Yamada, T. Molecular biology of the Ets family of transcription factors. Gene 303, 11–34 (2003).
Asano, Y. et al. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol. Cell. Biol. 29, 425–434 (2009).
Czuwara-Ladykowska, J., Shirasaki, F., Jackers, P., Watson, D. K. & Trojanowska, M. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J. Biol. Chem. 276, 20839–20848 (2001).
Jinnin, M. et al. α2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Res. 33, 1337–1351 (2005).
Kubo, M. et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am. J. Pathol. 163, 571–581 (2003).
Nakerakanti, S. S., Kapanadze, B., Yamasaki, M., Markiewicz, M. & Trojanowska, M. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J. Biol. Chem. 281, 25259–25269 (2006).
Glass, C. K. & Ogawa, S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev. Immunol. 6, 44–55 (2006).
Shi-wen, X. et al. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford) 49, 259–263 (2010).
Wu, M. et al. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am. J. Pathol. 174, 519–533 (2009).
Ameshima, S. et al. Peroxisome proliferator-activated receptor gamma (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ. Res. 92, 1162–1169 (2003).
Guignabert, C. et al. Tie2-mediated loss of peroxisome proliferator-activated receptor-γ in mice causes PDGF receptor-β-dependent pulmonary arterial muscularization. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L1082–L1090 (2009).
Hansmann, G. et al. An antiproliferative BMP-2/PPARγ/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J. Clin. Invest. 118, 1846–1857 (2008).
Hansmann, G. et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation. Circulation 115, 1275–1284 (2007).
Summer, R. et al. Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L432–L438 (2009).
Lepparanta, O. et al. Transcription factor GATA-6 is expressed in quiescent myofibroblasts in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 42, 626–632 (2010).
Mano, T., Luo, Z., Malendowicz, S. L., Evans, T. & Walsh, K. Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery. Circ. Res. 84, 647–654 (1999).
Perlman, H., Suzuki, E., Simonson, M., Smith, R. C. & Walsh, K. GATA-6 induces p21(Cip1) expression and G1 cell cycle arrest. J. Biol. Chem. 273, 13713–13718 (1998).
Ghatnekar, A. V. et al. The role of GATA-6 in pulmonary arterial hypertension in scleroderma patients. Arthritis Rheum. 60, 1266 (2009).
Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M. & Kalluri, R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 67, 10123–10128 (2007).
Zeisberg, E. M., Potenta, S. E., Sugimoto, H., Zeisberg, M. & Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282–2287 (2008).
Leask, A. et al. Dysregulation of transforming growth factor β signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum. 46, 1857–1865 (2002).
Pannu, J. et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum. 58, 2528–2537 (2008).
Lin, S. L., Kisseleva, T., Brenner, D. A. & Duffield, J. S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617–1627 (2008).
Sundberg, C., Ivarsson, M., Gerdin, B. & Rubin, K. Pericytes as collagen-producing cells in excessive dermal scarring. Lab. Invest. 74, 452–466 (1996).
Kulozik, M., Hogg, A., Lankat-Buttgereit, B. & Krieg, T. Co-localization of transforming growth factor β2 with α1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J. Clin. Invest. 86, 917–922 (1990).
Wang, Y., Fan, P. S. & Kahaleh, B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 54, 2271–2279 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Trojanowska, M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 6, 453–460 (2010). https://doi.org/10.1038/nrrheum.2010.102
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.102
This article is cited by
-
Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications
Arthritis Research & Therapy (2022)
-
Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis
Arthritis Research & Therapy (2022)
-
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review
Neurological Sciences (2022)
-
Improving Vascular Regeneration Performance of Electrospun Poly(ε-Caprolactone) Vascular Grafts via Synergistic Functionalization with VE-Cadherin/VEGF
Advanced Fiber Materials (2022)
-
Correlation of retinal and choroidal microvascular impairment in systemic sclerosis
Orphanet Journal of Rare Diseases (2021)